Design: We performed a retrospective cohort study of 2135 adult patients from 2 Boston teaching hospitals. All patients had 25(OH)D concentrations measured before hospitalization between 1993 and 2010. The main outcome measure was HABSI, which was defined as positive blood cultures from samples drawn 48 h after hospital admission. Coagulase-negative Staphylococcus isolates were not considered to be bloodstream infections. Associations between 25(OH)D groups and HABSI were estimated by using bivariable and multivariable logistic regression models. Adjusted ORs were estimated with the inclusion of covariate terms thought to plausibly interact with both 25(OH)D concentration and HABSI. Results: Compared with patients with 25(OH)D concentrations $30 ng/mL, patients with concentrations ,30 ng/mL had higher odds of HABSI. For 25(OH)D concentrations ,10 ng/mL, the OR was 2.33 (95% CI: 1.45, 3.74); for 25(OH)D concentrations from 10 to 19.9 ng/mL, the OR was 1.60 (95% CI: 1.04, 2.46); and for 25(OH)D concentrations from 20 to 29.9 ng/mL, the OR was 1.13 (95% CI: 0.69, 1.84). After adjustment for age, sex, race (nonwhite compared with white), patient type (medical compared with surgical), and DeyoCharlson index, the ORs of HABSI were 1.95 (95% CI: 1.22, 3.12), 1.36 (95% CI: 0.89, 2.07), and 0.98 (95% CI: 0.60, 1.62), respectively. Conclusions: The analysis of 2135 adult patients showed that 25 (OH)D concentrations ,10 ng/mL before hospitalization were associated with significantly increased odds of developing HABSI. These data support the initiation of randomized trials to test the role of vitamin D supplementation in HABSI prevention.
INTRODUCTION
Hospital-acquired infections (HAIs) 4 are common in the United States with an incidence of 22 cases/1000 admissions (1) . Each year, w2 million new cases of nosocomial infections account for nearly 100,000 potentially avoidable deaths (2) . Patients with HAIs incur substantial excess annual health care expenditures ($28 billion-$45 billion), driven primarily by an increase in the hospital length of stay (3) . The most common HAIs in the United States in order of frequency are catheterrelated urinary tract infections, surgical site infections, pneumonias, and hospital-acquired bloodstream infections (HABSIs) (2) . Although HABSIs account for only 11-14% of all nosocomial infections, they account for a disproportionate share of the hospital length of stay, cost, and mortality attributable to HAIs (2) (3) (4) .
Strategies to decrease the incidence of HABSI focus on the control of environmental factors including provider hand hygiene, skin decontamination before the placement of invasive lines, antiseptic-impregnated catheters, and the use of prophylactic antibiotics (5) . Significant declines in HABSI rates, but not eradication, have been noted after adoption of prevention strategies (6) . Although it is known that derangements in immune function and disruption of natural barrier sites can predispose patients to infectious complications (7) , few studies have explored potentially modifiable host factors that may decrease risk of HABSI.
Evidence has suggested that vitamin D is a key regulator of the innate and adaptive immune system (8) . Indeed, low serum 25-hydroxyvitamin D [25(OH)D] concentrations have been hypothesized to be an important risk factor for infection susceptibility and the development of HABSIs (9) . Because suboptimal 25(OH)D concentrations are increasingly prevalent in the general population of the United States (10-13), we performed a 2-center observational study of adult patients in whom 25(OH)D concentrations had been measured for nonspecific reasons #1 y before hospitalization. The objective of this study was to test our hypothesis that vitamin D status before hospital admission is associated with risk of developing HABSI.
SUBJECTS AND METHODS

Source population
We abstracted laboratory and administrative data from the electronic medical records of the of the following 2 teaching hospitals in Boston, MA: Brigham and Women's Hospital (BWH), with 777 beds and Massachusetts General Hospital (MGH) with 902 beds. The 2 hospitals provide primary as well as tertiary care to an ethnically and socioeconomically diverse population within eastern Massachusetts and the surrounding region.
Data sources
Data on all patients admitted to the BWH or MGH between 3 August 1993 and 5 January 2011 were obtained through the Research Patient Data Registry, which is a computerized registry that serves as a central data warehouse for all inpatient and outpatient records at Partners HealthCare sites, which include the BWH and MGH. The Research Patient Data Registry has been used for other clinical research studies (14) (15) (16) (17) (18) . Institutional review board approval for the study was granted by the Partners Human Research Committee.
Study population
During the study period, there were 24,787 individual patients admitted, aged $18 y, with serum 25(OH)D measured between 7 and 365 d before hospitalization and who were assigned a Diagnostic Related Group (DRG). Exclusions included the following: 23 foreign patients without Social Security Numbers because vital status in this study was determined by the Social Security Administration Death Master File, 618 patients with missing laboratory data, 216 patients who received high-dose vitamin D supplementation (50,000 IU ergocalciferol) between the 25(OH)D draw and hospital admission, 3093 patients who received critical care because the data had been previously analyzed (14) , and 18,702 patients who did not have blood cultures drawn .48 h after hospital admission. Thus, 2135 patients constituted the total study population. Compared with the study cohort, the parent cohort of 24,787 patients had the same average age but more women (62%), more surgery patients (40%), a higher mean 25(OH)D value (28 ng/mL), and a lower 30-d mortality rate (4%).
Exposure of interest and comorbidities
The exposure of interest was prehospital serum 25(OH)D concentration obtained 7-365 d before the date of hospital admission and categorized a priori as ,10 ng/mL (,25 nmol/L), 10-19.9 ng/mL (25-49.9 nmol/L), 20-29.9 ng/mL (50-74.9 nmol/L), and $30 ng/mL (75 nmol/L). All cutoffs were adapted from existing national clinical guidelines (19) . In a secondary analysis, we categorized a prehospital serum 25(OH)D concentration ,20 ng/mL as a cutoff for vitamin D inadequacy, as suggested in a recent Institute of Medicine report (20) .
We used the Deyo-Charlson index to assess the burden of chronic illness (21) by using International Classification of Diseases (Ninth Edition) coding algorithms ,which are well studied and validated (22, 23 
25(OH)D assays
Between 1993 and 2011, the following different assays were used at the 2 hospitals: a chemiluminescence assay, radioimmunoassay, or liquid chromatography-mass spectroscopy (LC-MS). Dates, times, and types of 25(OH)D assay were recorded. The clinical laboratories where the assays were performed were Clinical Laboratory Improvement Amendments certified. The 25(OH)D assays were tested for imprecision by clinical laboratories at the 2 hospitals. Imprecision testing with human serum specimens showed within-run CVs of #4.5% for the chemiluminescence assay, #10.8% for the radioimmunoassay, and #8.6% for the LC-MS. Method corrections were not used when institutions changed assays. Data on the comparability of 25(OH)D assays has been performed by other groups (25) , but because this was a retrospective, observational study, the determination of between-method assay differences was not possible.
Endpoints
The primary endpoint was the presence of HABSI. Information on blood cultures for the study cohort was obtained from microbiology reports from the computerized registry at the hospitals under study. All cohort patients had blood cultures drawn. Blood cultures were defined as positive if aerobic, anaerobic, or fungal blood cultures grew identifiable organisms. Patients with positive blood cultures were considered to have bloodstream infections (26) (27) (28) . Bloodstream infections were characterized as hospital acquired if they were drawn .48 h after hospital admission. Patients with coagulase-negative staphylococcus (CoNS) isolates were considered not to have a bloodstream infection.
Power calculations and statistical analysis
We assumed that the bloodstream infection incidence would increase 5% in patients with prehospital 25(OH)D concentrations ,20 ng/mL compared with in patients with concentrations $20 ng/mL (29) . With an a error level of 5% and a power of 80%, the minimum sample size required for our primary endpoint (HABSI) was 1414 total patients. Categorical variables were described by frequency distribution and compared across 25(OH)D groups by using contingency tables and chi-square testing. Continuous variables were examined graphically (eg, by using a histogram or box plot) and in terms of summary statistics (means 6 SDs, medians, or IQRs) and compared across exposure groups by using ANOVA. The outcome considered was HABSI.
Unadjusted associations between 25(OH)D groups and HABSI were estimated by using bivariable logistic regression models. Adjusted ORs were estimated by using multivariable logistic regression models with the inclusion of covariate terms thought to plausibly be associated with both the 25(OH)D concentration and HABSI. For the primary model (HABSI), the specification of each continuous covariate (as linear compared with categorical terms) was adjudicated by the empiric association with the primary outcome by using Akaike's information criterion; the overall model fit was assessed by using the Hosmer-Lemeshow test. Models for secondary analyses were specified identically to the primary model. Locally weighted scatter plot smoothing was used to graphically represent (30, 31) the relation between the prehospital 25(OH)D concentration and risk of HABSI. All P values were 2-tailed; values ,0.05 were considered statistically significant. All analyses were performed with STATA 12.0MP statistical software (StataCorp LP).
RESULTS
Characteristics of the study population are shown in Table 1 . Most patients were women (55%), were white (80%), and had medically related DRGs (69%). The mean (6SD) age at hospital admission was 61 Patient characteristics of the study cohort were stratified according to prehospital 25(OH)D concentrations ( Table 2 ). Factors that significantly differed between stratified groups included age, sex, and race. As indicated in Table 3 , the 25(OH)D concentration, age, sex, and patient type were significant predictors of HABSI. The in-hospital mortality rate was 6%. Thirty-and 90-d mortality rates were 7% and 14%, respectively.
Primary outcome
A prehospital 25(OH)D concentration ,10 ng/mL was a strong predictor of HABSI ( Table 4 ). The odds of HABSI in patients with 25(OH)D concentrations ,10 ng/mL were 2.3-fold those in patients with concentrations $30 ng/mL. A 25(OH)D concentration ,10 ng/mL remained a significant predictor of the odds of HABSI after adjustment for age, sex, race, DeyoCharlson index, and patient type. Adjusted odds of HABSI in the group of patients with 25(OH)D concentrations ,10 ng/mL were 2.0-fold those in patients with concentrations $30 ng/mL (Table 4) . Additional adjustment for assay type (chemiluminescence, radioimmunoassay, or LC-MS) did not materially alter point estimates; the group with 25(OH)D concentrations ,10 ng/mL had an OR of HABSI of 1.91 (95% CI: 1.17, 3.13) relative to that in the groups with 25(OH)D concentrations $30 ng/mL after adjustment for age, sex, race (nonwhite compared with white), patient type (medical compared with surgical), DeyoCharlson index, and assay type. Although limited by the statistical power, results did not materially differ by hospital site.
Subanalyses
Although the statistical power was compromised, when patients who had vitamin D status measured .90 d before hospital admission were excluded (n = 1238), the odds of HABSI in patients with 25(OH)D concentrations ,10 ng/mL were 2.18 (95% CI: 1.20, 3.93) relative to those in patients with concentrations $30 ng/mL. The multivariable adjusted odds of HABSI in patients with 25(OH)D concentrations ,10 ng/mL was 1.87 (95% CI: 1.03, 3.42) relative to those in patients with concentrations $30 ng/mL.
As per the recommendation of the Institute of Medicine (20) (Table 4) . After multivariable adjustment per our primary analysis, the OR of HABSI in patients with prehospital 25(OH)D concentrations ,20 ng/mL was 1.7-fold that of those with concentrations $20 ng/mL (Table 4) .
Another sensitivity analysis was performed to evaluate the data relative to the 25(OH)D assay used. Although the statistical power was compromised, we showed that patients with 25(OH)D Table 5 (Table 5 ).
Effect modification
Analyses that were based on fully adjusted models were performed to evaluate the 25(OH)D-HABSI association, and the P-interaction was determined to explore any evidence of an effect modification. We individually tested for the effect modification by creatinine, blood urea nitrogen, white blood count, assay type, and season of 25(OH)D draw by adding an interaction term to the multivariate models. None of these variables emerged as an effect modifier of the association between 25(OH)D and HABSI (P-interaction: . 0.20 for all variables tested). An additional effect-modification analysis showed that the association between 25(OH)D and HABSI was not modified by serum calcium .10.5 mg/dL (P-interaction: HABSI = 0.50). Additional effect modification analysis showed that the association between 25(OH)D and HABSI was not modified by the hospital that provided care (P-interaction: HABSI = 0.14) or the time Unadjusted associations between 25(OH)D groups and hospital-acquired bloodstream infections were estimated by using bivariable logistic regression models. Adjusted ORs were estimated by using multivariable logistic regression models with the inclusion of covariate terms thought to plausibly be associated with both 25(OH)D concentrations and hospital-acquired bloodstream infections. Estimates were adjusted for age, sex, race (white compared with nonwhite), patient type (surgical compared with medical), and the Deyo-Charlson index. between 25(OH)D draw and hospital admission (P-interaction: HABSI = 0.16). In addition, individually running the adjusted model with and without terms for assay type, creatinine, blood urea nitrogen, white blood count, calcium, hematocrit, and the time between 25(OH)D draw and hospital admission, the HABSI estimates in each case were similar. The odds of HABSI in the group with 25(OH)D concentrations ,10 ng/mL were 1.91 (95% CI: 1.17, 3.13) with additional adjustment for assay type; there was an OR of 1.90 (95% CI: 1.18, 3.04) with the time between 25(OH)D draw and admission, an OR of 1.95 (95% CI: 1.22, 3.12) with calcium, and OR of 1.99 (95% CI: 1.24,v3.21) with creatinine, an OR of 1.95 (95% CI: 1.22, 3 .13) with the white blood cell count, and ad OR of 1.98 (95% CI: 1.24, 3.18) with season, all relative to the group with 25(OH)D concentrations $30 ng/mL. These results indicated that the 25(OH)D-HABSI relation was not materially confounded by assay type, year of hospital admission, creatinine, blood urea nitrogen, white blood count, hematocrit, or time between 25(OH)D draw and hospital admission.
DISCUSSION
In this study, we investigated whether prehospital vitamin D status was associated with risk of HABSI. Our data showed that prehospital 25(OH)D concentrations ,10 ng/mL were associated with a significant increase in odds of HABSI in hospitalized adults. The finding remained on multivariable analyses and suggested that vitamin D supplementation may provide a novel approach to lowering HABSI risk. However, because our study was observational and not interventional, a causal relation between vitamin D status and outcomes could not be inferred from these data alone.
Our observation of increased odds of HABSI with 25(OH)D concentrations ,10 ng/mL may have been related to a depressed innate immunity. Vitamin D receptors are expressed in cells of the immune system, such as T cells, activated B cells, and dendritic cells (32) (33) (34) (35) (36) . Low 25(OH)D concentrations are associated with depressed macrophage phagocytosis, chemotaxis, and proinflammatory cytokine production (37) . Vitamin D links Tolllike receptor activation and innate immunity to upregulate the expression of antimicrobial peptides cathelicidin and b-defensin (38) (39) (40) . In humans, cathelicidin has been shown to have potent activity against bacteria, viruses, fungi, and mycobacteria. In addition, vitamin D is important for the interferon-g-dependent T cell response to infection (41) . In murine sepsis, vitamin D supplementation improves coagulation variables and inhibits endotoxemia (42) (43) (44) . The convergence of mechanistic evidence of vitamin D-mediated immunodulation and our clinical data on risk of HABSI in patients with 25(OH)D concentrations ,10 ng/mL raised a number of questions that merit additional investigation.
The current study had potential limitations. Although cohort studies are not the highest level of clinical evidence, they can illustrate the existence or absence of a true effect and direct future research (45) . Observational studies may be limited by potential confounding, reverse causation, and the lack of a randomly distributed exposure. An ascertainment bias may exist because the patient cohort under study had vitamin D status measured for unknown reasons that may have been absent in other hospitalized patients. These differences may have decreased the generalizability of our results to all hospitalized patients. Despite adjustment for multiple potential confounders, there may still have been residual confounding that contributed to observed differences in outcomes. Specifically, low 25(OH)D concentrations may have been a marker for the general condition of the patient, for which we were unable to fully adjust. In addition, we were not able to adjust for use of glucocorticoids, which may have adversely affected vitamin D status (46) and may have increased patient susceptibility to infection (47) . We were also unable to adjust for sun exposure, immobilization, excessive alcohol intake, smoking status, or genetic factors (48) (51) . In addition, we do not know if patients who had 25(OH)D concentrations determined by different assays had differences in treatment outside our health system. These issues will need to be addressed by other groups as they try to replicate and extend our findings. Last, we note that CoNS isolates were not considered to be bloodstream infections because CoNS are common skin commensals and are frequent contaminants of blood cultures (52) . True CoNS bacteremia has an increasing incidence, is associated with mortality and morbidity, and has gained greater importance as a pathogen (53) . Although the exclusion of CoNS isolates may have underestimated the incidence of true bloodstream infections, the analysis of our study cohort with the inclusion of all CoNS isolates did not materially alter the 25(OH)D-HABSI association (data not shown). In addition, indwelling central venous catheters are important risk factors for HABSI (54) . However, because of limitations of the data, we were unable to determine which patients had central venous catheters or the site from which the blood cultures may have been obtained.
The current study has several strengths. For example, our study had sufficient numbers of patients to ensure the adequate reliability of our estimates (n = 2135; HABSI rate = 8%). We had sufficient statistical power to detect a clinically relevant difference in HABSI if one existed. And although the Deyo-Charlson index accounts for chronic conditions such as diabetes and chronic renal failure that may alter immune function (55), it is not clear if illness severity influences vitamin D status at the time of hospital admission (20, 56) . However, the preservation of the 25(OH)D-HABSI association after the exclusion of patients with 25(OH)D drawn .90 d before hospitalization and the absence of effect modification or confounding relative to the time between the 25(OH)D draw and hospital admission suggested that the likelihood of reverse causation was low.
In conclusion, these data show that prehospital 25(OH)D concentrations ,10 ng/mL are associated with increased odds of HABSI in a large cohort of hospitalized patients. Our work supports the hypothesis that better vitamin D status may play an important protective role against nosocomial infections (9) . Although Vitamin D supplementation may decrease the incidence of acute respiratory tract infections in ambulatory settings (57), we believe that our results provide clinical evidence of a potential link between vitamin D and outcomes of hospitalized patients. We illustrate the possibility that even small changes in vitamin D status may affect HABSI. Despite our observations, the supplementation of vitamin D in the hospitalized adult cannot currently be advocated solely for HABSI. Longitudinal studies are required to confirm our findings and to further investigate the mechanisms underlying these observations. If confirmed, randomized, placebo-controlled trials will be needed to determine whether vitamin D-supplementation therapy before or at the time of hospital admission might have a benefit in improving outcomes in hospitalized patients.
